Clinical Trials

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT04288089 2026-02-27

A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

31 enrolled 12 charts

Breast Neoplasms

NCT04546009 2026-02-20

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

992 enrolled

Breast Neoplasms

NCT03332797 2026-02-13

A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

181 enrolled

Breast Neoplasms

NCT02499146 2026-02-11

Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer

Phase 1 Completed

26 enrolled 40 charts

Advanced Breast Cancer

NCT05501886 2026-02-10

VIKTORIA-1

701 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT05909397 2026-02-10

VERITAC-3

59 enrolled

Breast Neoplasms

NCT06757634 2026-02-05

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Phase 3 Recruiting

674 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT03616587 2026-01-28

SERENA-1

396 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT05468697 2026-01-23

MK-6482-024

60 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT07002177 2026-01-07

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Phase 1/2 Recruiting

196 enrolled

Breast Neoplasms

NCT05563220 2026-01-06

ELEVATE

Phase 1/2 Recruiting

435 enrolled

Phase 2 Active not recruiting

Breast Neoplasms

NCT05226871 2025-11-25

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

35 enrolled

BreastHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms

NCT03284957 2025-11-24

AMEERA-1

Phase 1/2 Terminated

136 enrolled 60 charts

Breast Neoplasms

NCT05266105 2025-11-24

A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients

60 enrolled

Breast Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

430 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05935748 2025-11-12

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Phase 2 Terminated

18 enrolled

Genitourinary

Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT02297438 2025-10-27

A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]

Phase 3 Completed

340 enrolled 29 charts

Breast Neoplasms, Neoplasm Metastasis

NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Other solid neoplasmSarcoma

610 enrolled

Advanced Solid Tumors

NCT04567420 2025-10-16

DARE

Phase 2 Recruiting

70 enrolled

Breast Neoplasms

NCT04711252 2025-10-14

SERENA-4

1,370 enrolled

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Skin Diseases

NCT05216432 2025-09-22

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Phase 1 Recruiting

930 enrolled

Breast Neoplasms

NCT04478266 2025-09-11

AMEERA-5

Phase 3 Terminated

1,068 enrolled 21 charts

Breast Neoplasms

NCT04224272 2025-08-01

A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer

Phase 2 Completed

51 enrolled 10 charts

Breast Neoplasms

NCT06570031 2025-07-02

ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

46 enrolled

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT05759949 2025-05-16

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

Phase 1 Completed

41 enrolled

Phase 1 Not yet recruiting

Breast Neoplasms

NCT06941142 2025-04-23

A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

382 enrolled

Advanced Breast Cancer

NCT05384119 2025-02-21

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Phase 1 Terminated

6 enrolled